» Articles » PMID: 37202772

Engineered Extracellular Vesicles Mediated CRISPR-induced Deficiency of IQGAP1/FOXM1 Reverses Sorafenib Resistance in HCC by Suppressing Cancer Stem Cells

Overview
Publisher Biomed Central
Specialty Biotechnology
Date 2023 May 18
PMID 37202772
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Sorafenib resistance poses therapeutic challenges in HCC treatment, in which cancer stem cells (CSCs) plays a crucial role. CRISPR/Cas9 can be utilized as a potential technique to overcome the drug resistance. However, a safe, efficient and target specific delivery of this platform remains challenging. Extracellular vesicles (EVs), the active components of cell to cell communication, hold promising benefits as delivery platform.

Results: Herein we report the normal epithelial cell -derived EVs engineered with HN3(HLC9-EVs) show competing tumor targeting ability. Anchoring HN3 to the membrane of the EVs through LAMP2, drastically increased the specific homing of HLC9-EVs to GPC3Huh-7 cancer cells rather than co-cultured GPC3LO2 cells. Combination therapy of HCC with sorafenib and HLC9-EVs containing sgIF to silence IQGAP1 (protein responsible for reactivation of Akt/PI3K signaling in sorafenib resistance) and FOXM1 (self-renewal transcription factor in CSCs attributed to sorafenib resistance), exhibited effective synergistic anti-cancer effect both in vitro and in vivo. Our results also showed that disruption of IQGAP1/FOXM1 resulted in the reduction of CD133 population that contribute to the stemness of liver cancer cells.

Conclusion: By reversing sorafenib resistance using combination therapeutic approach with engineered EVs encapsulated CRISPR/Cas9 and sorafenib, our study foreshadows a path for a better, accurate, reliable and successful anti-cancer therapy in the future.

Citing Articles

Exosome crosstalk between cancer stem cells and tumor microenvironment: cancer progression and therapeutic strategies.

Li Q, He G, Yu Y, Li X, Peng X, Yang L Stem Cell Res Ther. 2024; 15(1):449.

PMID: 39578849 PMC: 11583673. DOI: 10.1186/s13287-024-04061-z.


Promising nanotherapeutics of stem cell extracellular vesicles in liver regeneration.

Guo N, Wang Y, Wen Z, Fan X Regen Ther. 2024; 26:1037-1047.

PMID: 39569342 PMC: 11576938. DOI: 10.1016/j.reth.2024.09.016.


Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth.

Yan Z, Huang L, Zhang X, Yu X, Huang R Sci Rep. 2024; 14(1):18444.

PMID: 39117725 PMC: 11310191. DOI: 10.1038/s41598-024-67437-4.


CRISPR-mediated ablation of TP53 and EGFR mutations enhances gefitinib sensitivity and anti-tumor efficacy in lung cancer.

Yoon A, Lee S, Kim J, Park Y, Koo T, Yun C Mol Ther. 2024; 32(10):3618-3628.

PMID: 39066480 PMC: 11489544. DOI: 10.1016/j.ymthe.2024.07.017.


Modulatory effects of cancer stem cell-derived extracellular vesicles on the tumor immune microenvironment.

Li X, Zhang C, Yue W, Jiang Y Front Immunol. 2024; 15:1362120.

PMID: 38962016 PMC: 11219812. DOI: 10.3389/fimmu.2024.1362120.


References
1.
Gauthier A, Ho M . Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol Res. 2012; 43(2):147-54. PMC: 3574194. DOI: 10.1111/j.1872-034X.2012.01113.x. View

2.
Wei T, Choi S, Buehler D, Anderson R, Lambert P . A PI3K/AKT Scaffolding Protein, IQ Motif-Containing GTPase Associating Protein 1 (IQGAP1), Promotes Head and Neck Carcinogenesis. Clin Cancer Res. 2019; 26(1):301-311. PMC: 6942630. DOI: 10.1158/1078-0432.CCR-19-1063. View

3.
Wang L, Li F, Dang L, Liang C, Wang C, He B . In Vivo Delivery Systems for Therapeutic Genome Editing. Int J Mol Sci. 2016; 17(5). PMC: 4881452. DOI: 10.3390/ijms17050626. View

4.
Wang N, Wang S, Li M, Hu B, Liu L, Yang S . Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies. Ther Adv Med Oncol. 2019; 10:1758835918816287. PMC: 6304707. DOI: 10.1177/1758835918816287. View

5.
Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View